Prevalence of and prognosis for poor immunological recovery by virally suppressed and aged HIV-infected patients

Lina Fan, Penghui Li, Aiping Yu, Dan Liu, Ziyu Wang, Yue Wu, Defa Zhang, Meiyin Zou, Ping MaFrontiers in Medicine 2023 · DOI

This study, published in Frontiers in Medicine, investigates why nearly 30% of older HIV-infected patients fail to achieve healthy immune recovery despite successful viral suppression through Antiretroviral Therapy (ART). The researchers found that "inadequate immunological responders" (INRs) face nearly triple the mortality risk, with cardiovascular disease and tumors serving as both significant risk factors for, and consequences of, poor immune recovery.

TL;DR

Even when HIV is "undetectable," many patients aged 60+ fail to restore their CD4+ T cell counts, leading to significantly higher mortality. This study identifies low baseline T cell counts, cardiovascular disease, and tumors as primary drivers of this failure, while suggesting that specific ART drug classes (INSTIs and PIs) may offer better recovery prospects than older regimens.

What Problem Does This Paper Address?

Modern Antiretroviral Therapy (ART) is highly effective at stopping HIV replication, often reducing the viral load to undetectable levels. However, a subset of patients—known as Inadequate Immunological Responders (INRs)—fails to see a corresponding rise in their CD4+ T cell counts (a key marker of immune health).

This is a growing concern for the "aging with HIV" population. As patients live longer, they face a "double whammy" of natural immunosenescence (age-related immune decline) and chronic HIV-related inflammation. This paper seeks to quantify the prevalence of INRs among patients aged 60 and older and determine how non-AIDS-related comorbidities (like heart disease and cancer) influence their long-term prognosis.

Methods

The researchers conducted a retrospective cohort study at Tianjin Second People’s Hospital, China.

  • Participants: 507 HIV-positive patients aged ≥60 who had been on ART for at least two years and maintained viral suppression (HIV RNA < 20 copies/ml).
  • Definitions:
    • INR: CD4+ T cell count < 350 cells/μl after 2 years of ART.
  • IR (Immunological Responders): CD4+ T cell count > 350 cells/μl.
  • Analysis: The team used multivariate logistic regression to identify risk factors for poor immune recovery and Cox proportional regression models to evaluate mortality risks. They also utilized Kaplan–Meier curves to visualize survival differences between groups.

Datasets

The study utilized a clinical dataset derived from the electronic medical records of Tianjin Second People’s Hospital, covering patients who initiated ART between August 2009 and December 2020. The final analysis focused on 507 individuals after excluding those with incomplete data, loss to follow-up, or virologic failure.

Key Insights and Ideas

  • The Prevalence of Stagnation: Roughly 29.6% of the elderly cohort were classified as INRs. This suggests that for nearly one in three older patients, suppressing the virus is not enough to fix the immune system.
  • Comorbidities as Drivers, Not Just Outcomes: While it is well-known that poor immunity leads to illness, this study highlights that existing Cardiovascular Disease (CVD) and tumors are independently associated with the failure to recover CD4+ cells in the first place.
  • The "Baseline" Shadow: The strongest predictor of failing to reach a healthy T cell count was starting ART with a very low count (below 50 cells/μl). This underscores the critical importance of early diagnosis and treatment, even in older populations.
  • Drug Selection Matters: Patients on Integrase Strand Transfer Inhibitor (INSTI) or Protease Inhibitor (PI) based regimens had a significantly lower probability of being INRs compared to those on older NNRTI-based regimens.

Key Results

  • Mortality Risk: INRs had a significantly higher mortality rate (13.1% vs. 4.2% in responders). The adjusted odds ratio (AOR) for death among INRs was 2.83.
  • Risk Factors for INR:
    • CVD: AOR 2.45 (95% CI: 1.22–4.93).
  • Tumors: AOR 3.06 (95% CI: 1.09–8.56).
  • Low Baseline CD4+ (<50): AOR 15.48 (massive increase in risk).
  • Protective Factors: Switching ART drugs during treatment was associated with decreased mortality (AOR: 0.14), suggesting that proactive clinical management can mitigate some risks.

Limitations and Future Work

The authors acknowledge several limitations:

  1. Retrospective Design: The study relies on existing medical records, which may have inherent biases or missing nuances regarding the timing of non-AIDS disease onset.
  2. Single-Center Data: Data was pulled from one tertiary health center in Tianjin, which may not represent the global or even national diversity of the aging HIV population.
  3. Self-Reporting: Some comorbidities like CVD were self-reported, which might lead to underestimation compared to clinical screenings.

Future Work: The authors suggest prospective studies are needed to determine if specifically tailoring ART drug selection (e.g., prioritizing INSTIs) can actively improve immune reconstitution and survival in the elderly.

Summary updated

Abstract

These results tend to demonstrate appropriate drug selection at ART initiation and prevention of non-AIDS complications during ART decreased mortality of and an inadequate immunological response in aged HIV infected patients.
BibTeX
@inproceedings{fan2023prevalence,
  author = {Lina Fan and Penghui Li and Aiping Yu and Dan Liu and Ziyu Wang and Yue Wu and Defa Zhang and Meiyin Zou and Ping Ma},
  title = {{Prevalence of and prognosis for poor immunological recovery by virally suppressed and aged HIV-infected patients}},
  booktitle = {Frontiers in Medicine},
  year = {2023},
  doi = {10.3389/fmed.2023.1259871},
}
Figure